Filgrastim Approval Information - Licensing Action

Proper name: Filgrastim
Tradename: Neupogen
Manufacturer: Amgen, Inc, Thousand Oaks, CA, License #1080
Indication for Use: New indication for use in patients with acute myeloid leukemia
Approval Date: 4/2/98
Type of submission: Biologics license application supplement


Approval Letter (PDF)

Label (PDF)

Reviews - (PDF)
      Biostatistical (7 pages)
      Clinical (20 pages)

Page Last Updated: 04/06/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English